Pharmafile Logo

HRA Pharma UK

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

Bayer symbol

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

- PMLiVE

GSK shares promising phase 3 results for linerixibat in PBC-related itch

Pruritus is experienced by up to 90% of patients with the rare liver disease

Digital PI Compliance

Why Pharma’s Digital PI Compliance Problem Needs a Cross-Functional Fix

In many pharma teams, the responsibility for keeping prescribing information (PI) up to date online falls into a grey area. > Regulatory signs it off. > Marketing publishes it. >...

Genetic Digital

- PMLiVE

GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

- PMLiVE

GSK’s five-in-one meningococcal vaccine recommended by CDC advisory committee

Penmenvy combines the antigenic components of GSK's approved Bexsero and Menveo vaccines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links